IPO - Opus Genetics, Inc.

Form Type: 424B5

Filing Date: 2025-03-20

Corporate Action: Ipo

Type: New

Accession Number: 000114036125009727

Filing Summary: Opus Genetics, Inc. is offering shares of common stock and warrants to purchase common stock through a preliminary prospectus supplement. The prospectus outlines an offering of common stock and warrants wherein each share is sold together with a warrant. This new offering is tied to a recent merger with Private Opus and includes various financing details and conditions pertinent to the offering. Notably, the common stock's last trading price before the filing was $1.15 per share. The document indicates a substantial upcoming enrollment phase for the LCA5 Phase 1/2 clinical trial, and provides a detailed summary of recent corporate strategies and future clinical developments, including addressing key regulations and risk factors affecting the company's operations. The offering also involves pre-funded warrants to avoid excess ownership limits by certain purchasers. Additionally, the company's strategic transition and developments post-merger, such as the acquisition of gene therapy programs for inherited retinal diseases, reflect its evolving operational landscape.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-01-13

Corporate Action: Ipo

Type: New

Accession Number: 000114036125000950

Filing Summary: On January 13, 2025, Opus Genetics, Inc. filed a prospectus supplement related to a public offering of up to $40,000,000 in common stock. The company has entered into a sales agreement with Leerink Partners LLC to facilitate this offering. The shares will be sold at the market as per SEC regulations and Leerink is not obligated to sell a minimum number of shares. Compensation for Leerink will be 3% of gross proceeds from sales. The filing also indicates the termination of a prior sales agreement and notes previous sales amounting to approximately $26.4 million. The company, which is developing gene therapies for retinal diseases, recently acquired a private corporation and is advancing its gene therapy programs. It has ongoing clinical trials for its lead product targeting an inherited retinal disease. As of September 30, 2024, the company reported having $36.6 million in cash, sufficient to support operations into 2026. The filing includes standard risk factors associated with investing in its securities and outlines the company's use of proceeds from this offering for general corporate purposes and research and development activities.

Document Link: View Document